Immunome Inc 8-K, filed Mar 25, 2021
Immunome Inc. (IMNM)
About this 8-K
Immunome Inc filed this 8-K on March 25, 2021.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (state or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer
Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name
of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On March 25, 2021, Immunome, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2020 and provided a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release dated March 25, 2021 (furnished herewith) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMMUNOME, INC. | ||
| By: |
/s/ Purnanand D. Sarma | |
|
Purnanand D. Sarma, Ph.D. President and Chief Executive Officer | ||
Dated: March 25, 2021
Exhibit 99.1
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
- IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing -
- IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies -
- Raised $44.9 million in gross proceeds in NASDAQ IPO -
- Program updates expected in 2Q 2021 -
Exton, Pa., March 25, 2021 – Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
“The fourth quarter of 2020 was a transformational period for Immunome thanks to our successful initial public offering on the NASDAQ exchange, which raised $44.9 million in gross proceeds,” said Purnanand Sarma, Ph.D., President and CEO of Immunome. “That positive momentum continued into 2021, with our recent announcements covering the isolation of antibodies capable of neutralizing SARs-CoV-2 variants in pseudovirus testing as part of our IMM-BCP-01 program, and the advancement of IMM-ONC-01, our proprietary antibody against IL-38 for the potential treatment of solid tumors including malignancies of high unmet need such as cancers of the head and neck and the lung, into IND-enabling studies.”
Dr. Sarma continued: “Looking ahead, we expect to provide development program updates in the second quarter of 2021, and to file INDs for both IMM-BCP-01 and IMM-ONC-01 in 2021. We remain excited about the prospects for both of our current development programs and reiterate the confidence we have in our discovery engine to move one to two new candidates into IND-enabling studies per year. I very much look forward to updating you on our progress in the months ahead.”
Financial Highlights
| · | Cash and cash equivalents: As of December 31, 2020, cash and cash equivalents totaled $39.8 million. |
| · | Research and development (R&D) expenses: R&D expenses for the three months ended December 31, 2020 were $1.8 million. R&D expenses for the year ended December 31, 2020 were $7.5 million. |
| · | General and administrative (G&A) expenses: G&A expenses for the three months ended December 31, 2020 were $2.2 million. G&A expenses were $4.8 million for the year ended December 31, 2020. |
| · | Net loss: Net loss attributable to common stockholders was $4.1 million, or $0.40 per share, for the three months ended December 31, 2020. Net loss attributable to common stockholders was $17.8 million, or $5.26 per share, for the year ended December 31, 2020. |
| · | As of December 31, 2020, Immunome had 10,634,245 shares of common stock outstanding. |
About Immunome
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome’s beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM-ONC-01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek,” “potential” and similar expressions. Forward-looking statements are based on Immunome’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones; Immunome’s ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunome’s ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Immunome’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome’s filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
Immunome Contact
Purnanand Sarma, PhD
Chief Executive Officer
Immunome, Inc.
investors@immunome.com
Investor Contact
Laurence Watts
Managing Director
Gilmartin, LLC
laurence@gilmartinir.com
Immunome Media Contact
Megan McGrath or Nick Chang
MacDougall
781-235-3060
mmcgrath@macbiocom.com or nchang@macbiocom.com
###
IMMUNOME, INC.
Statements of operations
(in thousands, except share and per share amounts)
| Three Months Ended December 31, | Year ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 1,835 | $ | 2,432 | $ | 7,486 | $ | 8,823 | ||||||||
| General and administrative | 2,238 | 456 | 4,775 | 1,525 | ||||||||||||
| Total operating expenses | 4,073 | 2,888 | 12,261 | 10,348 | ||||||||||||
| Loss from operations | (4,073 | ) | (2,888 | ) | (12,261 | ) | (10,348 | ) | ||||||||
| Other expenses: | ||||||||||||||||
| Change in fair value of warrant liability | 11 | — | (5,538 | ) | — | |||||||||||
| Interest expense, net | (11 | ) | (34 | ) | (38 | ) | (96 | ) | ||||||||
| Total other expenses | - | (34 | ) | (5,576 | ) | (96 | ) | |||||||||
| Net loss | $ | (4,073 | ) | $ | (2,922 | ) | $ | (17,837 | ) | $ | (10,444 | ) | ||||
| Per share information: | ||||||||||||||||
| Net loss per share of common stock, basic and diluted | $ | (0.40 | ) | $ | (2.66 | ) | $ | (5.26 | ) | $ | (9.55 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 10,190,607 | 1,097,907 | 3,389,592 | 1,093,959 | ||||||||||||
IMMUNOME, INC.
Balance sheets
(in thousands, except share and per share amounts)
| December 31, | ||||||||
| 2020 | 2019 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 39,766 | $ | 2,543 | ||||
| Prepaid expenses and other current assets | 3,128 | 579 | ||||||
| Total current assets | 42,894 | 3,122 | ||||||
| Property and equipment, net | 1,531 | 1,700 | ||||||
| Restricted cash | 100 | 100 | ||||||
| Other assets | — | 138 | ||||||
| Total assets | $ | 44,525 | $ | 5,060 | ||||
| Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Current portion of capital lease obligations | $ | — | $ | 239 | ||||
| Current portion of long-term debt | 366 | — | ||||||
| Current portion of equipment loan payable | 113 | 212 | ||||||
| Accounts payable | 1,187 | 548 | ||||||
| Accrued expenses and other current liabilities | 1,372 | 666 | ||||||
| Total current liabilities | 3,038 | 1,665 | ||||||
| Equipment loan payable, net of current portion | — | 113 | ||||||
| Long-term debt, net of current portion | 134 | — | ||||||
| Deferred rent | 8 | 18 | ||||||
| Total liabilities | 3,180 | 1,796 | ||||||
| Series A convertible preferred stock | — | 38,894 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Common stock | 1 | — | ||||||
| Additional paid-in capital | 95,738 | 927 | ||||||
| Accumulated deficit | (54,394 | ) | (36,557 | ) | ||||
| Total stockholders’ equity (deficit) | 41,345 | (35,630 | ) | |||||
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $ | 44,525 | $ | 5,060 | ||||